Skip to Main Content
CKG
Home
Home
Home
TKG
Author details
Breadcrumb
Author Details
Full Name
Christopher A Bristow
Affiliation
The University of Texas MD Anderson Cancer Center
ORCID
Career Start Year
2005
Papers
56
H Index
32
Expertise
CM4AI Collaborator
PMID
Paper Title
Journal Title
Published Year
36350677
PICKLES v3: the updated database of pooled in vitro CRISPR knockout library essentiality screens.
Nucleic Acids Res
2023
36350677
PICKLES v3: the updated database of pooled in vitro CRISPR knockout library essentiality screens.
Nucleic Acids Res
2023
36440915
Easy NanoString nCounter data analysis with the NanoTube.
Bioinformatics
2023
36747713
Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistance.
bioRxiv
2023
36658425
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.
Nat Med
2023
36747713
Combined KRAS<sup>G12C</sup> and SOS1 inhibition enhances and extends the anti-tumor response in KRAS<sup>G12C</sup>-driven cancers by addressing intrinsic and acquired resistance.
bioRxiv
2023
36440915
Easy NanoString nCounter data analysis with the NanoTube.
Bioinformatics
2023
36658425
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials.
Nat Med
2023
35138907
A functional genomic approach to actionable gene fusions for precision oncology.
Sci Adv
2022
35944232
Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set.
JCO Clin Cancer Inform
2022
35138907
A functional genomic approach to actionable gene fusions for precision oncology.
Sci Adv
2022
35944232
Shared Nearest Neighbors Approach and Interactive Browser for Network Analysis of a Comprehensive Non-Small-Cell Lung Cancer Data Set.
JCO Clin Cancer Inform
2022
33158812
Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress.
Cancer Res
2021
33745946
Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.
Gastroenterology
2021
34117030
Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition.
Cancer Res
2021
34108622
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.
Oncogene
2021
33839689
Oncogenic <i>KRAS</i> Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis.
Cancer Discov
2021
34330913
PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma.
Nat Commun
2021
34309585
Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer.
JCI Insight
2021
33158812
Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress.
Cancer Res
2021
34518211
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.
Cancer Res
2021
34777916
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanoma.
Oncoimmunology
2021
34359705
Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways.
Cancers (Basel)
2021
33839689
Oncogenic <i>KRAS</i> Recruits an Expansive Transcriptional Network through Mutant p53 to Drive Pancreatic Cancer Metastasis.
Cancer Discov
2021
33745946
Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer.
Gastroenterology
2021
34518211
Oxidative Phosphorylation Is a Metabolic Vulnerability in Chemotherapy-Resistant Triple-Negative Breast Cancer.
Cancer Res
2021
34777916
Short-term treatment with multi-drug regimens combining BRAF/MEK-targeted therapy and immunotherapy results in durable responses in <i>Braf</i>-mutated melanoma.
Oncoimmunology
2021
34117030
Targeting Glucose Metabolism Sensitizes Pancreatic Cancer to MEK Inhibition.
Cancer Res
2021
34359705
Synthetic Lethality Screening Highlights Colorectal Cancer Vulnerability to Concomitant Blockade of NEDD8 and EGFR Pathways.
Cancers (Basel)
2021
34309585
Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer.
JCI Insight
2021
34330913
PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma.
Nat Commun
2021
34108622
Combined inhibition of DDR1 and CDK4/6 induces synergistic effects in ER-positive, HER2-negative breast cancer with PIK3CA/AKT1 mutations.
Oncogene
2021
32928921
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
Cancer Res
2020
32928921
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib.
Cancer Res
2020
33087697
Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers.
Nat Commun
2020
33118821
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.
J Med Chem
2020
33118821
Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties.
J Med Chem
2020
33087697
Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers.
Nat Commun
2020
30625329
Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation.
Cell Rep
2019
31719531
ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer.
Nat Commun
2019
31815044
BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening.
Am J Cancer Res
2019
31610796
Global impact of somatic structural variation on the DNA methylome of human cancers.
Genome Biol
2019
31557131
YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.
JCI Insight
2019
30625329
Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation.
Cell Rep
2019
30986992
Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer.
Cancers (Basel)
2019
31492820
Predictive Signatures Inform the Effective Repurposing of Decitabine to Treat KRAS-Dependent Pancreatic Ductal Adenocarcinoma.
Cancer Res
2019
30867319
ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism.
Sci Transl Med
2019
30996079
Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state.
Sci Transl Med
2019
31815044
BRCA1 identified as a modulator of temozolomide resistance in P53 wild-type GBM using a high-throughput shRNA-based synthetic lethality screening.
Am J Cancer Res
2019
31719531
ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer.
Nat Commun
2019
1 - 50 of 112
Column Actions
Search
Recommended Authors
Rohan Bareja
Case Western Reserve University
Career Start Year
2017
Number of shared co-authors
4
Huwate Yeerna
Moores Cancer Center, University of California
Career Start Year
2015
Number of shared co-authors
2
Andrew Goodspeed
University of Colorado Denver | Anschutz Medical Campus
Career Start Year
2013
Number of shared co-authors
0
Tuo Zhang
Weill Cornell Medical College.
Career Start Year
2013
Number of shared co-authors
1
Rahul K Kollipara
McDermott Center for Human Growth and Development.
Career Start Year
2010
Number of shared co-authors
1
Aleksandra M Michalowski
Center for Cancer Research, National Cancer Institute
Career Start Year
2010
Number of shared co-authors
0
Matan Hofree
Broad Institute of Harvard and MIT
Career Start Year
2010
Number of shared co-authors
8
Frederick S Vizeacoumar
College of Medicine, University of Saskatchewan
Career Start Year
2010
Number of shared co-authors
1
Ganiraju C Manyam
the University of Texas MD Anderson Cancer Center
Career Start Year
2009
Number of shared co-authors
37
Sander R van Hooff
Princess Maxima Center for Pediatric Oncology
Career Start Year
2008
Number of shared co-authors
0
Justin Y Newberg
Foundation Medicine Inc.
Career Start Year
2008
Number of shared co-authors
5
David A Quigley
University of California-San Francisco
Career Start Year
2008
Number of shared co-authors
5
Pichai Raman
Center for Data-Driven Discovery in Biomedicine, Children's Hospital of Philadelphia
Career Start Year
2006
Number of shared co-authors
14
James C Costello
University of Colorado Anschutz Medical Campus
Career Start Year
2006
Number of shared co-authors
11
Matti Nykter
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year
2006
Number of shared co-authors
18
Henry Yang
Cancer Science Institute of Singapore, National University of Singapore
Career Start Year
2005
Number of shared co-authors
3
Jesse S Boehm
Broad Institute of Harvard and MIT
Career Start Year
2004
Number of shared co-authors
29
Aik Choon Tan
Huntsman Cancer Institute, The University of Utah
Career Start Year
2003
Number of shared co-authors
4
Olivier Elemento
Meyer Cancer Center
Career Start Year
2002
Number of shared co-authors
33
Yidong Chen
The University of Texas Health Science Center at San Antonio
Career Start Year
2001
Number of shared co-authors
7
Luciano G Martelotto
Monash University
Career Start Year
2000
Number of shared co-authors
3
Wenyan Zhong
Oncology R&D
Career Start Year
2000
Number of shared co-authors
8
Tobias Sj??blom
Uppsala University
Career Start Year
1999
Number of shared co-authors
1
Andrew J Gentles
Stanford Center for Biomedical Informatics Research, Stanford University
Career Start Year
1999
Number of shared co-authors
24
Li Ding
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year
1997
Number of shared co-authors
80
Andrea Califano
Columbia University
Career Start Year
1993
Number of shared co-authors
41
Samuel Aparicio
University of British Columbia
Career Start Year
1993
Number of shared co-authors
12
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year
1989
Number of shared co-authors
43
Pablo Tamayo
University of California San Diego
Career Start Year
1988
Number of shared co-authors
30
Francisca Vazquez
Broad Institute of MIT and Harvard
Career Start Year
1979
Number of shared co-authors
19
row(s) 1 - 30 of 30
Collaborators
Timothy P Heffernan
Co-authored papers
27
Sahil Seth
The University of Texas MD Anderson Cancer Center
Co-authored papers
13
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Co-authored papers
9
Raju Kucherlapati
Harvard Medical School
Co-authored papers
8
Lixing Yang
University of Chicago, USA University of Chicago Comprehensive Cancer Center
Co-authored papers
8
Peter J Park
Harvard Medical School
Co-authored papers
8
Angeliki Pantazi
Harvard Medical School, Brigham and Women's Hospital
Co-authored papers
7
Anirban Maitra
The University of Texas MD Anderson Cancer Center
Co-authored papers
7
Xiaojia Ren
University of Kentucky College of Medicine
Co-authored papers
7
Alexei Protopopov
The University of MD Anderson Cancer Center
Co-authored papers
7
Jeffrey J Kovacs
Co-authored papers
6
Chad J Creighton
Co-authored papers
6
Angela Hadjipanayis
Harvard Medical School, Brigham and Women's Hospital
Co-authored papers
6
Semin Lee
Ulsan National Institute of Science and Technology (UNIST)
Co-authored papers
6
Jonathan G Seidman
Harvard Medical School
Co-authored papers
6
Jiabin Tang
The University of MD Anderson Cancer Center
Co-authored papers
6
Xingzhi Song
The University of Texas MD Anderson Cancer Center
Co-authored papers
6
Harshad S Mahadeshwar
The University of MD Anderson Cancer Center
Co-authored papers
6
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers
5
Lynda Chin
Co-authored papers
5
Andrea Viale
The University of Texas MD Anderson Cancer Center
Co-authored papers
5
Funda Meric-Bernstam
University of Texas MD Anderson Cancer Center
Co-authored papers
5
Scott Kopetz
University of Texas MD Anderson Cancer Center
Co-authored papers
5
Lynda Chin
The University of MD Anderson Cancer Center
Co-authored papers
5
Amy G Robertson
Present address: Dxige Research Inc.
Co-authored papers
4
Huandong Sun
Co-authored papers
4
Han Liang
MD Anderson Cancer Center
Co-authored papers
4
Roel G W Verhaak
Yale School of Medicine
Co-authored papers
4
Manolis Kellis
Massachusetts Institute of Technology
Co-authored papers
4
Alexander J Lazar
The University of Texas MD Anderson Cancer Center
Co-authored papers
4
1 - 30